Injectable Contraceptive, Depo-Provera, Produces Erratic Beating Patterns in Patient-Specific Induced Pluripotent Stem Cell-derived Cardiomyocytes with Type 2 Long QT Syndrome
Long QT syndrome type 2 (LQT2) is caused by pathogenic variants in KCNH2. LQT2 may manifest as QT prolongation on an ECG and present with arrhythmic syncope/seizures, sudden cardiac arrest/death. Oral progestin-based contraceptives may increase the risk of LQT2-triggered cardiac events in women. We previously reported on a LQT2 woman with recurrent cardiac events temporally related and attributed to the progestin-based contraceptive, medroxyprogesterone acetate ( “Depo-Provera”, Depo). (Source: Heart Rhythm)
Source: Heart Rhythm - March 6, 2023 Category: Cardiology Authors: Alexa M. Pinsky, Xiaozhi Gao, Sahej Bains, CS John Kim, Julien Louradour, Katja E. Odening, David J. Tester, John R. Giudicessi, Michael J. Ackerman Source Type: research
Discovery of novel inhibitor of 11 beta-hydroxysteroid dehydrogenase type 1 using in silico structure-based screening approach for the treatment of type 2 diabetes
ConclusionThe docking study revealed that hydrocortisone cypionate has a higher binding affinity than carbenoxolone and its other analogs. The molecular dynamics simulation indicated the stability of the docked complex of 11 β-HSD1 and hydrocortisone cypionate. These findings indicate the potential use of this FDA approved drug in the treatment of type 2 diabetes. However, validation by in vitro inhibitory studies and clinical trials on type 2 diabetes patients is essential to confirm the current findings. (Source: Journal of Diabetes and Metabolic Disorders)
Source: Journal of Diabetes and Metabolic Disorders - March 6, 2023 Category: Endocrinology Source Type: research
Injectable contraceptive Depo-Provera produces erratic beating patterns in patient-specific induced pluripotent stem cell –derived cardiomyocytes with long QT syndrome type 2
Long QT syndrome type 2 (LQT2) is caused by pathogenic variants in KCNH2. LQT2 may manifest as QT prolongation on an electrocardiogram and present with arrhythmic syncope/seizures and sudden cardiac arrest/death. Progestin-based oral contraceptives may increase the risk of LQT2-triggered cardiac events in women. We previously reported on a woman with LQT2 and recurrent cardiac events temporally related and attributed to the progestin-based contraceptive medroxyprogesterone acetate ( “Depo-Provera” [Depo]). (Source: Heart Rhythm)
Source: Heart Rhythm - March 6, 2023 Category: Cardiology Authors: Alexa M. Pinsky, Xiaozhi Gao, Sahej Bains, CS John Kim, Julien Louradour, Katja E. Odening, David J. Tester, John R. Giudicessi, Michael J. Ackerman Source Type: research
Injectable contraceptive Depo-Provera induces erratic beating patterns in patient-specific induced pluripotent stem cell –derived cardiomyocytes with long QT syndrome type 2
Long QT syndrome type 2 (LQT2) is caused by pathogenic variants in KCNH2. LQT2 may manifest as QT prolongation on an electrocardiogram and present with arrhythmic syncope/seizures and sudden cardiac arrest/death. Progestin-based oral contraceptives may increase the risk of LQT2-triggered cardiac events in women. We previously reported on a woman with LQT2 and recurrent cardiac events temporally related and attributed to the progestin-based contraceptive medroxyprogesterone acetate ( “Depo-Provera” [Depo] MilliporeSigma, Catalog# 1378001, St. (Source: Heart Rhythm)
Source: Heart Rhythm - March 6, 2023 Category: Cardiology Authors: Alexa M. Pinsky, Xiaozhi Gao, Sahej Bains, Changsung John Kim, Julien Louradour, Katja E. Odening, David J. Tester, John R. Giudicessi, Michael J. Ackerman Source Type: research
Getting Up to Date with What Works: A Systematic Review on the Effectiveness and Safety of Task Sharing of Modern Methods in Family Planning Services
CONCLUSION: The evidence suggests that self-injection of DMPA-SC and tubal ligation performed by associate clinicians are safe and effective. These findings should be complemented with the evidence on the feasibility and acceptability of task sharing of these methods. The review protocol was registered with PROSPERO CRD42021283336.PMID:36817856 | PMC:PMC9936454 | DOI:10.1155/2023/8735563 (Source: Biomed Res)
Source: Biomed Res - February 23, 2023 Category: Research Authors: Tieba Millogo Eunice Chomi Seni Kouanda Moazzam Ali Source Type: research
Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial
AbstractThe Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial found no substantial difference in HIV acquisition risk between women randomised to injectable intramuscular depot medroxyprogesterone acetate (DMPA-IM), copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant. We evaluated post-randomization sexual behavior using an objective marker of condomless vaginal sex in a subset of participants. We conducted a sub-study among 458 ECHO participants at three sites (Cape Town, Johannesburg, Kisumu) to evaluate the frequency of condomless vaginal sex, measured by prostate specific antigen (PSA...
Source: AIDS and Behavior - February 22, 2023 Category: Infectious Diseases Source Type: research
Invasiveness of endometrial cancer cell lines is potentiated by estradiol and blocked by a traditional medicine Guizhi Fuling at clinically relevant doses
Front Oncol. 2023 Jan 16;12:1015708. doi: 10.3389/fonc.2022.1015708. eCollection 2022.ABSTRACTThe Traditional Chinese medicine, Guizhi Fuling (here called Fuling), has been confirmed in meta-analysis studies to reduce recurrence of endometriosis and improve pregnancy outcomes; however, the possible use of Fuling as a fertility-preserving treatment in endometrial cancer has not previously been tested. Results here are the first to demonstrate dose-dependent inhibition of cell motility by Fuling in two endometrial cancer cell lines, classified as Grade I which is responsive to progesterone treatment, and Grade III (MFE-280) ...
Source: Cancer Control - February 2, 2023 Category: Cancer & Oncology Authors: Sidra Khan Alanah Varricchio Carmela Ricciardelli Andrea J Yool Source Type: research
Correction to: Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial
Clin Infect Dis. 2023 Jan 23:ciac309. doi: 10.1093/cid/ciac309. Online ahead of print.NO ABSTRACTPMID:36689296 | DOI:10.1093/cid/ciac309 (Source: Herpes)
Source: Herpes - January 23, 2023 Category: Infectious Diseases Source Type: research
Correction to: Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial
Clin Infect Dis. 2023 Jan 23:ciac309. doi: 10.1093/cid/ciac309. Online ahead of print.NO ABSTRACTPMID:36689296 | DOI:10.1093/cid/ciac309 (Source: Herpes)
Source: Herpes - January 23, 2023 Category: Infectious Diseases Source Type: research
Hormonal contraceptive use, bone density and biochemical markers of bone metabolism in British Army recruits
Conclusions
DMPA use was associated with increased bone turnover and decreased cortical bone integrity of the tibia. Lower cortical bone integrity in DMPA users was possibly mediated by increased intracortical remodelling, but trabecular bone was not affected by contraceptive use. (Source: Journal of the Royal Army Medical Corps)
Source: Journal of the Royal Army Medical Corps - January 23, 2023 Category: General Medicine Authors: Coombs, C. V., O'Leary, T. J., Tang, J. C. Y., Fraser, W. D., Greeves, J. P. Tags: Original research Source Type: research
Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study
CONCLUSION: Pregnancy after MPA therapy is associated with a high risk of placenta accreta. In cases in which the frequency of D&C is high, placenta accreta should be considered.PMID:36662363 | DOI:10.1007/s10147-023-02297-y (Source: Cancer Control)
Source: Cancer Control - January 20, 2023 Category: Cancer & Oncology Authors: Maki Oishi Yoshifumi Kasuga Yuka Fukuma Asuka Hamuro Junko Tamai Yuya Tanaka Keita Hasegawa Takuma Yoshimura Satoru Ikenoue Daigo Ochiai Wataru Yamagami Mamoru Tanaka Source Type: research
Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology
CONCLUSION: In this survey, we confirmed that FS treatment in Japan is centered on MPA alone and in combination with metformin, and that the treatment efficacy is similar to that reported in previous reports. A multicenter survey study in Japan showed FS treatment for young AEH and EC patients in compliance with the indications is feasible.PMID:36659833 | DOI:10.3802/jgo.2023.34.e38 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - January 20, 2023 Category: OBGYN Authors: Kimio Ushijima Naotake Tsuda Wataru Yamagami Akira Mitsuhashi Mikio Mikami Nobuo Yaegashi Takayuki Enomoto Source Type: research
